Lba9 Pr Association between Tumor Egfr and Kras Mutation Status and Clinical Outcomes in Nsclc Patients Randomized to Sorafenib plus Best Supportive Care (bsc) or Bsc Alone: Subanalysis of the Phase Iii Mission Trial
نویسندگان
چکیده
book and program 642 NOTCH AND DLL4 EXPRESSION IN BEVACIZUMAB-TREATED COLON CANCER PATIENTS 646 PHASE II STUDY OF S-1 PLUS LEUCOVORIN (1 WEEK TREATMENT REGIMEN FOLLOWED BY 1 WEEK REST PERIOD) IN PATIENTS WITH UNTREATED METASTATIC COLORECTAL CANCER IN JAPAN AND CHINA: COMPARING RESULTS OF EACH COUNTRY AND UPDATING OVERALL SURVIVAL 651 RETROSPECTIVE ANALYSIS OF PATHOLOGICAL RESPONSE IN COLORECTAL CANCER LIVER METASTASES FOLLOWING TREATMENT WITH BEVACIZUMAB: UPDATED FINDINGS 659 BASELINE CEA SERUM LEVELS PREDICT THE EFFICACY OF BEVACIZUMAB-BASED TREATMENT IN ADVANCED COLORECTAL CANCER abstracts Annals of Oncology
منابع مشابه
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
PURPOSE Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. ...
متن کاملChemotherapy Plus Best Supportive Care versus Best Supportive Care in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
BACKGROUND The use of chemotherapy has been proposed to increase the effectiveness of best supportive care (BSC) in patients with non-small cell lung cancer (NSCLC). Previous trials reported inconsistent findings regarding the efficacy and safety of chemotherapy on overall survival (OS) and treatment-related mortality. We performed a systematic review and meta-analysis to evaluate the effects o...
متن کاملAssociation of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.
BACKGROUND Cetuximab-induced hypomagnesemia has been associated with improved clinical outcomes in advanced colorectal cancer (CRC). We explored this relationship from a randomized clinical trial of cetuximab plus best supportive care (BSC) versus BSC alone in patients with pretreated advanced CRC. PATIENTS AND METHODS Day 28 hypomagnesemia grade (0 versus ≥1) and percent reduction (<20% vers...
متن کاملImpact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
Purpose. This retrospective, nonrandomized study investigated the effect of imatinib rechallenge plus best supportive care (BSC) on overall survival after imatinib and sunitinib treatment for patients with locally advanced or metastatic gastrointestinal stromal tumor (GIST). Methods. Twenty-six patients who had previously been exposed to both imatinib and sunitinib were enrolled in this study. ...
متن کاملSafety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
BACKGROUND To assess the efficacy and safety of fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, in metastatic colorectal cancer (mCRC) patients. METHODS A phase Ib open-label study and phase II randomized, placebo-controlled trial compared the efficacy of fruquintinib plus best supportive care (BSC) with placebo plus BSC in mCRC patients with ≥2 lines of prior t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2012